Eledon Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Eledon Pharmaceuticals Inc.
- Former names
- Novus Therapeutics, Inc. Tokai Pharmaceuticals Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Irvine
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ELDN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001404281
Board of directors
-
Allan Kirk · DirectorSince 2023
-
David-Alexandre C. Gros · Director · Chief Executive OfficerSince 2023
-
Gary A. Lyons · DirectorSince 2023
-
James A. Robinson Jr. · DirectorSince 2023
-
Jan Hillson · DirectorSince 2023
-
John S. McBride · DirectorSince 2023
-
June Lee · DirectorSince 2023
-
Keith Katkin · DirectorSince 2023
-
Steven Perrin · Director · PresidentSince 2023
-
Walter C. Ogier · DirectorSince 2023
Chief executives
David-Alexandre C. Gros
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
0.0%
-
0.0%
-
0.0%
Board connections
4 of this board's directors also sit on 7 other boards.
- via Keith Katkin
- via Gary A. Lyons
- via Gary A. Lyons
- via Keith Katkin
- via June Lee
- via Gary A. Lyons
- via James A. Robinson Jr.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 31, 2026 | Steven Perrin Director, Officer (President) | Grant or award | +152,353 | — | — |
| Jul 31, 2026 | David-Alexandre C. Gros Director, Officer (Chief Executive Officer) | Grant or award | +354,454 | — | — |
| Jul 31, 2026 | Steven Perrin Director, Officer (President) | Shares withheld for tax | −72,138 | $3.38 | $243,826 |
| Jul 31, 2026 | David-Alexandre C. Gros Director, Officer (Chief Executive Officer) | Shares withheld for tax | −194,791 | $3.38 | $658,394 |
| Jan 10, 2026 | John S. McBride Director | Option exercise | +3,430 | — | — |
| Jan 10, 2026 | Jan Hillson Director | Option exercise | +3,430 | — | — |
| Jan 10, 2026 | Allan Kirk Director | Option exercise | +3,430 | — | — |
| Jan 10, 2026 | Keith Katkin Director | Option exercise | +8,575 | — | — |
| Jan 10, 2026 | June Lee Director | Option exercise | +3,430 | — | — |
| Jan 10, 2026 | James A. Robinson Jr. Director | Option exercise | +3,430 | — | — |
| May 9, 2024 | BVF INC/IL 10% owner | Open-market purchase | +1,031,385 | — | — |
| May 9, 2024 | BVF INC/IL 10% owner | Open-market purchase | +821,121 | — | — |
| May 9, 2024 | BVF INC/IL 10% owner | Open-market purchase | +75,431 | — | — |
| May 5, 2023 | Biotechnology Value Trading Fund OS LP See Explanation of Responses | Open-market purchase | +1,055,445 | — | — |
| May 5, 2023 | Biotechnology Value Trading Fund OS LP See Explanation of Responses | Open-market purchase | +837,146 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.